Melancholic depression is a severe subtype of major depressive disorder (MDD), often characterized by profound biological symptoms, significant functional impairment, and poor response to psychotherapy…
Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, often requiring innovative strategies beyond traditional antidepressants. A groundbreaking step in addressing this…
Transdermal selegiline is a monoamine oxidase inhibitor (MAOI) used as a treatment option for patients with treatment-resistant major depressive disorder (MDD). Why Transdermal Selegiline preferred…
When it comes to managing Major Depressive Disorder (MDD), the challenge often lies in patients who do not fully respond to first-line treatments like SSRIs…
Facebook LIVE 003: Join us for our third Facebook Live[May 18 at 10:30 am PST] Facebook LIVE is a new feature for our academy students.…
Major depressive disorder (MDD) remains a significant global health challenge, affecting millions of individuals and often leading to substantial impairment in daily functioning. While a…
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUAâ„¢, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder…
Monoamine Oxidase Inhibitors (MAOIs) have not only shown efficacy with treatment resistant depression, but are also found efficacious for the treatment of depression in the…
Trazodone belongs to a class of antidepressant medications called serotonin antagonists and reuptake inhibitors (SARIs). Traozodone is used more for insomnia treatment compared to MDD…
As medical professionals, we are often tasked with helping our patients navigate the complexities of grief and loss. Losing a loved one is a deeply painful…
We continue our lecture series “10 Augmentation Strategies for MDD” with our ninth lecture on the role of SAMe as an augmentation for major depressive…
We continue our lecture series “10 Augmentation Strategies for MDD” with our eighth lecture on the role of Pramipexole as an augmentation for major depressive…
We continue our lecture series “10 Augmentation Strategies for MDD” with our sixth lecture on the role of Stimulants as an augmentation for major depressive…
We continue our lecture series “10 Augmentation Strategies for MDD” with our fifth lecture on the role of Lamotrigine as an augmentation for major depressive…
We continue our lecture series “10 Augmentation Strategies for MDD” with our fourth lecture on the role of L-MethylFolate as an augmentation for major depressive…
We continue our lecture series “10 Augmentation Strategies for MDD” with our third lecture on the role of thyroid hormine as an augmentation for major…
We continue our lecture series “10 Augmentation Strategies for MDD” with our second lecture on the role of lithium as an augmentation for major depressive…
It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only…
On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in…
PSYCHIATRY EDUCATION FORUM ACADEMY’S LECTURE SERIES: MAJOR DEPRESSIVE DISORDER: 10 AUGMENTATION STRATEGIES Introduction Psychiatry Education Forum Academy continues to provide high-quality, evidence-based & practice-oriented discussions…
Psychiatry Education Forum Academy is excited to announce the release of Academy’s 19th Journal Club discussion today: This article was published in the NEJM on…
Depression with atypical features is defined as significant mood reactivity combined with two of the following clinical features: Hyperphagia Hypersomnia Leaden paralysis Pathological rejection sensitivity…
Psychiatry Education Forum Academy is excited to announce our next presentation’s release date for Sep 10, 2022: WATCH INTRODUCTION VIDEO https://youtu.be/Q01KwQTdTqM There are many plant-based…
On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of…
Recently Omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) have drawn the clinical attention for the treatment of major depressive disorder. The…
Once you have initiated antidepressants for MDD (Major Depressive Disorder) treatment and the patient has achieved remission, how long will you continue this current antidepressant…
Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. Hence, it is of clinical importance to have knowledge of…
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
We begin PEFA Journal Club’s updated schedule with our first journal club discussion today: Journal Club #1: The Psychopharmacology Algorithm Project at the Harvard South…
How do you decide between psychotherapy versus medications for the treatment of major depressive disorder? Depression severity is one of the criteria used to make…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
